Lilly’s EUA Timeline For COVID-19 Combo Antibody Depends On Safety Data, Manufacturing

Single neutralizing antibody moves to US FDA with data showing reduced hospitalization, while Lilly’s EUA filing for two-antibody combo awaits safety data and more certainty about production capabilities.